ASP.. Acerus Pharmaceuticals

Acerus to Report 2016 Financial Results and Host Investor Call

TORONTO--(BUSINESS WIRE)--

Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its financial results for the three and twelve month periods ending December 31, 2016 on Wednesday March 8, 2017 before the market opens and host a conference call on Wednesday, March 8, 2017 at 8:30 a.m. Eastern Time.

To access the call live, please dial 416-340-2216 or 1-866-225-2055. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 11:59 p.m. Eastern Time on Thursday, March 16, 2017 by dialing 905-694-9451 or 1-800-408-3053, using access code: 1212516#.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus currently markets two products in Canada: ESTRACE®, a product indicated for the symptomatic relief of menopausal symptoms; and NATESTO®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. Acerus’ pipeline includes two new innovative products: GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, used in the treatment of atrophic vaginitis, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a ‘use as required’ drug development candidate, aimed at addressing a significant unmet need for women with female sexual dysfunction.

For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

EN
28/02/2017

Underlying

ASP..Acerus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acerus Pharmaceuticals

 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Update

Acerus Update TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) and its previously announced sale and investment solicitation process (the “SISP”), the Company completed the previously announced transactions (the “Transaction”) with First Generation Capital Inc. (“First Generation”) as successful bidder under the SISP. The Transaction was approved by the Ontario Superior Court of Justice (Commercial List) (the “Court...

July 11, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Update

Acerus Update TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection pursuant to an order (the “Initial Order”) granted by the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). Pursuant to the Initial Order, Ernst & Young Inc. was appointed as monitor of the Company (in such capacity, the “Monitor”). As announced on March 14, 2023, the Court granted an order (the “SISP Ord...

May 26, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Announces Commencement of Court-Approved Sale and Investment So...

Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- On January 26, 2023, Acerus Pharmaceuticals Corporation and certain of its subsidiaries (collectively, “Acerus”) were granted protection pursuant to an order (the “Initial Order”) issued under the Companies’ Creditors Arrangement Act (the “CCAA Proceedings”) by the Ontario Superior Court of Justice (the “Canadian Court”). Ernst & Young Inc. was appointed Monitor of Acerus (in such capacity, the “Monitor”). On February 3, 2023, the Initial Order was amended a...

March 14, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Files For CCAA Protection

Acerus Files For CCAA Protection TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). As previously disclosed on September 21, 2022, Acerus unde...

January 26, 2023 1 EN
 PRESS RELEASE
Free
ASP.. Acerus Pharmace...

Acerus Announces Resignation of Director

Acerus Announces Resignation of Director TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately. About Acerus Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. Acerus’ shares trade on TSX under the symbol AS...

December 26, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch